Corcept Therapeutics CORT Accrued research and development expenses
Discontinued — last reported Q4 '25
Accrued research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept cort:AccruedResearchAndDevelopmentExpensesCurrent.
The official record: Corcept Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's accrued research and development expenses?
- Corcept Therapeutics (CORT) reported accrued research and development expenses of $33.95M in Q4 2025.
- How has Corcept Therapeutics's accrued research and development expenses changed year-over-year?
- Corcept Therapeutics's accrued research and development expenses increased by 0.3% year-over-year, from $33.87M to $33.95M.
- What is the long-term trend for Corcept Therapeutics's accrued research and development expenses?
- Over 4 years (2021 to 2025), Corcept Therapeutics's accrued research and development expenses has grown at a 28.5% compound annual growth rate (CAGR), from $12.44M to $33.95M.
- What does accrued research and development expenses mean?
- Unpaid expenses related to research and development work already performed.
- How do you interpret accrued research and development expenses?
- An increase often signals high R&D activity or the progression of clinical trials, while a decrease may suggest a slowdown in development projects.
- How does accrued research and development expenses compare across companies?
- Common in biotech and pharma; peers with active clinical pipelines will show significant accruals relative to their R&D budget.